Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment

Table 1

Patients followed.

No.	Gender	Age^1	Treatment			Hematologic
			Mo^2	Drug	Dosage/d	WBC×10^9/L	Lympho×10^9/L	Hb (gr/L)	Trc×10^9/L	HR^3	CCR^3
(1)	F	55	0	dg, HU	2000 mg	302.6	4.60	89	413	19	No
			8	IFN	5 MIU	16.2	1.45	130	188
			16	IFN	5 MIU	69.0	3.43	131	442
			22	IM	400 mg	10.5	2.86	124	399
			27	IM	400 mg	7.4	1.93	120	505
			39	IM	600 mg	4.0	1.11	120	175
			58	DS	100 mg	2.1	0.89	119	139
(2)	F	62	0	dg, HU	2500 mg	120.0	3.54	132	226	6	19
			6	IFN	3 MIU	4.7	1.49	151	163
			14	IFN	3 MIU	5.1	1.20	131	352
			15	IFN	5 MIU	5.8	0.91	140	356
			25	IM	400 mg	3.2	1.12	138	157
			43	IM	400 mg	7.0	1.38	130	430
			56	IM	400 mg	9.3	1.61	130	648
(3)	M	40	0	dg, HU	3000 mg	21.9	2.07	168	327	8	26
			7	IFN	3 MIU	8.1	1.08	163	262
			15	IFN	5 MIU	3.1	0.85	160	125
			26	IM	400 mg	4.2	1.10	146	246
			43	IM	400 mg	4.5	1.37	147	209
			58	IM	400 mg	3.9	1.01	158	210
(4)	M	60	0	dg, HU	2000 mg	198.5	5.06	110	550	6	36
			6	IFN	3 MIU	3.4	0.86	132	115
			12	IFN	5 MIU	3.4	1.21	137	152
			42	IM	400 mg	5.5	1.52	131	301
			56	IM	400 mg	3.5	1.56	136	311
(5)	M	33	0	dg, HU	2500 mg	99.7	5.91	142	169	2	40
			6	HU	2000 mg	9.9	3.56	145	151
			9	IFN	3 MIU	47.8	3.12	137	102
			40	IM	400 mg	4.3	1.69	142	202
			53	IM	400 mg	5.5	2.01	140	258
			58	IM	400 mg	6.6	1.88	136	266
(6)	F	35	0	dg, IFN	3 MIU	107.5	0.48	117	276	2	35
			10	IFN	3 MIU	4.4	0.76	101	182
			12	IM	400 mg	2.8	1.12	102	145
			36	DS	100 mg	2.9	1.61	89	233
			48	DS	100 mg	2.8	1.83	89	331
(7)	M	54	0	dg, HU	2000 mg	16.4	4.86	136	595	11	38
			7	HU	2000 mg	4.5	5.71	137	532
			20	HU	1000 mg	5.5	3.21	134	209
			34	IM	400 mg	6.9	1.23	134	206
			47	IM	400 mg	6.8	2.19	132	236
(8)	F	43	0	dg, IM	400 mg	26.9	4.05	144	464	2	17
			2	IM	400 mg	8.3	1.66	129	228
			9	IM	400 mg	6.0	1.76	123	185
			17	IM	400 mg	7.5	1.26	126	207
			31	IM	300 mg	7.6	1.73	120	239
			45	IM	300 mg	8.3	1.45	125	315
(9)	M	48	0	dg, IM	400 mg	439.2	6.16	81	184	7	No
			30	IM	400 mg	4.4	1.96	150	117
			44	IM	400 mg	5.4	1.41	149	112
(10)	F	38	0	dg, IM	400 mg	328.6	1.81	88	614	5	27
			7	IM	400 mg	3.0	1.32	121	200
			28	IM	400 mg	3.3	1.10	94	212
			36	IM	400 mg	4.9	0.98	103	236
(11)	F	61	0	dg,HU	2000 mg	16.8	5.31	109	1895	4	25
			29	DS	100 mg	5.8	2.02	100	519
			52	DS	100 mg	5.4	2.75	104	249

¹Age at enrollment; ²Mo: month; WBC: white blood cell count; Hb: hemoglobin; and Trc, thrombocyte count; HU: hydroxyurea; IFN: interferon-alpha 2a; IM: imatinib mesylate; DS: dasatinib; MIU, Millions International Units. ³The figure indicates month after diagnosis at which HR or CCR was first observed; “no” means that CCR was not achieved.
Notes: Patient no. 1 developed vasculitis (erythema nodosum), neutropenia which was subsequently treated with growth factors and immunoglobulins. Patients 6 and 7 had laboratory tests positive for autoimmune thyroiditis without any clinical manifestations.
Patient no. 11 decided to undergo homeopathic therapy and self-therapy with HU and was out of the evidence for some time. At the indicated interval, DS therapy was started because of pathological findings both in peripheral blood and bone marrow.